Edition:
Deutschland

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,719JPY
07:00 Uhr
Change (% chg)

¥9 (+0.53%)
Prev Close
¥1,710
Open
¥1,705
Day's High
¥1,730
Day's Low
¥1,703
Volume
1,515,800
Avg. Vol
1,563,635
52-wk High
¥2,069
52-wk Low
¥1,397

4506.T

Chart for 4506.T

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Japan segment manufactures and sells ethical and general use drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other... (more)

Buy/Sell

Sell Hold Buy
3.44 Mean rating from 9 analysts

Overall

Beta: 0.76
Market Cap(Mil.): ¥604,410.31
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.18

BRIEF-Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.

* Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC regarding their submissions of Abbreviated New Drug Applications for generic copies of LATUDA®(lurasidone HCl tablets)

BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film

* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes)

BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan

* POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN

BRIEF-Sumitomo Dainippon Pharma says result of early-retirement program

* Says 86 employees took up the offer of the early-retirement program announced on Sept. 27

BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD

* SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD

BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

* Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co

BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin

* Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries

BRIEF-Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia

* SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES

BRIEF-Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement

* Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR)

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.26%
Rohstoffe -0.33%
Industrie -0.26%
Konjunktur abhängige Waren & Dienstleistungen -0.23%
Konjunktur unabhängige Waren & Dienstleistungen -0.17%
Finanzindustrie -0.09%
Pharma -0.07%
Technologie -0.22%
Telekommunikation -0.06%